A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection

INTRODUCTION: Inhaled therapeutics may act to directly target and attenuate lung inflammation due to COVID-19. An inhalation form of a novel biologic drug, AMP5A, is being developed as an immunomodulatory agent to treat dysregulated immune responses and is being studied in hospitalized patients to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Roshon, Michael, Lemos-Filho, Luciano, Cherevka, Holli, Goldberg, Laura, Salottolo, Kristin, Bar-Or, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590808/
https://www.ncbi.nlm.nih.gov/pubmed/34775578
http://dx.doi.org/10.1007/s40121-021-00562-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590808/
https://www.ncbi.nlm.nih.gov/pubmed/34775578
http://dx.doi.org/10.1007/s40121-021-00562-z

Ejemplares similares